Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:53PM ET
0.6400
Dollar change
+0.0532
Percentage change
9.07
%
Index- P/E- EPS (ttm)-2.33 Insider Own19.32% Shs Outstand8.48M Perf Week8.47%
Market Cap5.43M Forward P/E21.33 EPS next Y0.03 Insider Trans0.00% Shs Float6.84M Perf Month3.23%
Income-7.79M PEG- EPS next Q-0.21 Inst Own20.25% Short Float1.05% Perf Quarter-39.05%
Sales5.18M P/S1.05 EPS this Y90.13% Inst Trans-4.73% Short Ratio1.15 Perf Half Y-37.86%
Book/sh-0.77 P/B- EPS next Y113.04% ROA-82.37% Short Interest0.07M Perf Year-69.81%
Cash/sh0.56 P/C1.14 EPS next 5Y40.00% ROE-1035.44% 52W Range0.56 - 2.42 Perf YTD-39.07%
Dividend Est.- P/FCF- EPS past 5Y15.68% ROI-321.93% 52W High-73.55% Beta0.21
Dividend TTM- Quick Ratio2.09 Sales past 5Y1418.11% Gross Margin96.10% 52W Low14.75% ATR (14)0.07
Dividend Ex-Date- Current Ratio2.25 EPS Y/Y TTM11.88% Oper. Margin-143.44% RSI (14)49.24 Volatility9.79% 11.70%
Employees4 Debt/Eq- Sales Y/Y TTM106.51% Profit Margin-150.41% Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-10.22% Payout- Rel Volume0.51 Prev Close0.59
Sales Surprise4.17% EPS Surprise-18.00% Sales Q/Q110.45% EarningsMar 14 AMC Avg Volume62.66K Price0.64
SMA200.26% SMA50-3.69% SMA200-44.15% Trades Volume27,089 Change9.07%
Date Action Analyst Rating Change Price Target Change
Jun-22-20Upgrade H.C. Wainwright Neutral → Buy $10
Mar-05-19Downgrade H.C. Wainwright Buy → Neutral
Mar-08-18Reiterated B. Riley FBR, Inc. Buy $10 → $5
Oct-19-17Resumed FBR & Co. Buy $10
Mar-16-17Reiterated Rodman & Renshaw Buy $6 → $9
Jan-30-17Upgrade Laidlaw Neutral → Buy $8
Jan-05-17Upgrade Rodman & Renshaw Neutral → Buy $2.50 → $6
Dec-23-16Reiterated Rodman & Renshaw Neutral $2 → $2.50
Jul-19-16Reiterated FBR Capital Outperform $17 → $9
Jul-19-16Downgrade Noble Financial Buy → Hold
Mar-21-24 04:15PM
Mar-15-24 01:58PM
06:56AM
Mar-14-24 04:05PM
Mar-07-24 04:10PM
07:30AM Loading…
Feb-14-24 07:30AM
Feb-09-24 07:30AM
Nov-30-23 12:16PM
Nov-27-23 08:30AM
Nov-14-23 08:30AM
Nov-09-23 08:30AM
Oct-31-23 08:30AM
Oct-23-23 06:30AM
Oct-18-23 08:30AM
Sep-14-23 08:30AM
08:30AM Loading…
Aug-10-23 08:30AM
Aug-07-23 08:30AM
Jul-25-23 08:30AM
Jun-14-23 08:30AM
May-15-23 04:05PM
May-09-23 07:00AM
May-04-23 08:30AM
May-01-23 08:30AM
Apr-20-23 08:30AM
Apr-06-23 08:30AM
Mar-24-23 07:36AM
Mar-23-23 08:30AM
Mar-21-23 04:05PM
Mar-15-23 08:30AM
Feb-21-23 07:00AM
07:00AM Loading…
Jan-30-23 07:00AM
Jan-18-23 08:30AM
Dec-07-22 08:30AM
Nov-30-22 08:30AM
Nov-12-22 08:03AM
Nov-09-22 04:30PM
04:05PM
Nov-02-22 08:30AM
Oct-20-22 08:44AM
Sep-20-22 08:30AM
Sep-14-22 08:30AM
Sep-06-22 08:30AM
Aug-16-22 08:30AM
Aug-10-22 04:30PM
04:05PM
Aug-03-22 08:30AM
Aug-01-22 08:30AM
Jul-06-22 08:30AM
Jun-15-22 08:30AM
Jun-08-22 08:30AM
May-23-22 07:00AM
May-18-22 08:30AM
May-17-22 08:30AM
May-10-22 04:05PM
May-03-22 08:30AM
Apr-26-22 11:36AM
08:54AM
08:30AM
Apr-19-22 08:30AM
Mar-10-22 08:30AM
Mar-08-22 04:05PM
Mar-01-22 08:30AM
Feb-24-22 08:30AM
Feb-17-22 08:30AM
Feb-02-22 08:30AM
Jan-04-22 08:30AM
Nov-10-21 04:05PM
Nov-03-21 08:30AM
Oct-20-21 08:30AM
Sep-29-21 08:30AM
Sep-10-21 07:53AM
Sep-01-21 08:30AM
Aug-16-21 07:20AM
Aug-12-21 04:05PM
Aug-05-21 08:30AM
Aug-02-21 08:30AM
Jul-14-21 08:30AM
Jun-29-21 08:30AM
Jun-15-21 08:30AM
Jun-08-21 08:30AM
Jun-02-21 08:30AM
May-27-21 08:30AM
May-14-21 08:30AM
May-12-21 02:30PM
May-05-21 08:30AM
Apr-06-21 08:30AM
Mar-30-21 08:30AM
Mar-14-21 04:52AM
Mar-11-21 06:05PM
04:05PM
02:30PM
Mar-04-21 04:05PM
Jan-20-21 08:30AM
Jan-13-21 08:03PM
04:02PM
08:30AM
Dec-17-20 08:55AM
Nov-10-20 08:30AM
Oct-26-20 08:30AM
Sep-09-20 08:30AM
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.